Hofseth Biocare ASA (HBC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hofseth Biocare ASA (HBC) has a cash flow conversion efficiency ratio of 0.167x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-4.65 Million ≈ $-489.52K USD) by net assets (Nkr-27.85 Million ≈ $-2.93 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Hofseth Biocare ASA defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Hofseth Biocare ASA - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Hofseth Biocare ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Hofseth Biocare ASA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hofseth Biocare ASA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
EQ Inc.
V:EQ
|
0.334x |
|
Hvidbjerg Bank
CO:HVID
|
0.002x |
|
SMCore.Inc
KQ:007820
|
-0.082x |
|
PBG S.A
SA:PTBL3
|
0.090x |
|
Francotyp-Postalia Holding AG
F:FPH
|
0.005x |
|
DK-Lok Corporation
KQ:105740
|
0.012x |
|
Avrot Industries Ltd
TA:AVRT
|
0.029x |
|
Adveritas Ltd
AU:AV1
|
-1.106x |
Annual Cash Flow Conversion Efficiency for Hofseth Biocare ASA (2010–2024)
The table below shows the annual cash flow conversion efficiency of Hofseth Biocare ASA from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see Hofseth Biocare ASA (HBC) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Nkr61.30 Million ≈ $6.45 Million |
Nkr-9.78 Million ≈ $-1.03 Million |
-0.160x | -337.71% |
| 2023-12-31 | Nkr41.14 Million ≈ $4.33 Million |
Nkr2.76 Million ≈ $290.54K |
0.067x | +121.99% |
| 2022-12-31 | Nkr148.03 Million ≈ $15.58 Million |
Nkr-45.17 Million ≈ $-4.75 Million |
-0.305x | +30.67% |
| 2021-12-31 | Nkr140.38 Million ≈ $14.77 Million |
Nkr-61.78 Million ≈ $-6.50 Million |
-0.440x | -88.34% |
| 2020-12-31 | Nkr263.76 Million ≈ $27.76 Million |
Nkr-61.63 Million ≈ $-6.49 Million |
-0.234x | +11.42% |
| 2019-12-31 | Nkr117.75 Million ≈ $12.39 Million |
Nkr-31.06 Million ≈ $-3.27 Million |
-0.264x | +20.71% |
| 2018-12-31 | Nkr86.04 Million ≈ $9.05 Million |
Nkr-28.62 Million ≈ $-3.01 Million |
-0.333x | +51.59% |
| 2017-12-31 | Nkr37.08 Million ≈ $3.90 Million |
Nkr-25.48 Million ≈ $-2.68 Million |
-0.687x | +45.24% |
| 2016-12-31 | Nkr53.56 Million ≈ $5.64 Million |
Nkr-67.23 Million ≈ $-7.07 Million |
-1.255x | -612.71% |
| 2015-12-31 | Nkr32.55 Million ≈ $3.42 Million |
Nkr7.97 Million ≈ $838.36K |
0.245x | +131.04% |
| 2014-12-31 | Nkr78.95 Million ≈ $8.31 Million |
Nkr-62.26 Million ≈ $-6.55 Million |
-0.789x | +41.55% |
| 2013-12-31 | Nkr62.00 Million ≈ $6.52 Million |
Nkr-83.65 Million ≈ $-8.80 Million |
-1.349x | -34.11% |
| 2012-12-31 | Nkr47.72 Million ≈ $5.02 Million |
Nkr-48.01 Million ≈ $-5.05 Million |
-1.006x | -522.78% |
| 2011-12-31 | Nkr120.53 Million ≈ $12.68 Million |
Nkr-19.47 Million ≈ $-2.05 Million |
-0.162x | +1.39% |
| 2010-12-31 | Nkr75.97 Million ≈ $7.99 Million |
Nkr-12.45 Million ≈ $-1.31 Million |
-0.164x | -- |
About Hofseth Biocare ASA
Hofseth BioCare ASA produces and sells health nutritional products for humans and pets in Norway, the United Kingdom, France, Belgium, Italy, Germany, rest of Europe, Japan, Asia, and the United States. The company offers ProGo, a bioactive peptide for weight management and metabolic health; OmeGo, a salmon oil that provides a full spectrum of fatty acids and omegas; CalGo and NT-II, which are ca… Read more